

VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results

August 13, 2019

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / August 13, 2019 / <u>VistaGen Therapeutics</u> (NASDAQ:VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced financial results for its fiscal year 2020 first quarter ended June 30, 2019.

"The next few months are potentially transformative for VistaGen, as we look forward to several clinical and regulatory milestones before year-end," stated <u>Shawn Singh, Chief Executive Officer of VistaGen</u>. "We have three differentiated clinical-stage drug candidates, each of which has an exceptional safety profile in studies to date and significant therapeutic and commercial potential in multiple large and growing CNS markets where current treatments are inadequate to meet the needs of millions of patients. Our team is focused on driving continued progress across our pipeline, and we are confident in our efforts to achieve our core goals - to deliver both safe and effective new generation treatments in neuropsychiatry and neurology for patients and extraordinary value to our loyal shareholders."

Financial Results for the Fiscal Quarter Ended June 30, 2019:

Net loss attributable to common stockholders for the fiscal quarter ended June 30, 2019 was approximately \$6.2 million, including approximately \$1.2 million of noncash charges, compared to \$4.2 million for the fiscal quarter ended June 30, 2018, primarily attributable to increased research and development activities relating to the Company's CNS drug development programs.

Research and development expense totaled \$4.3 million for the fiscal quarter ended June 30, 2019, compared with \$2.7 million for the fiscal quarter ended June 30, 2018. The increase in research and development expense is primarily related to the continued progress of ELEVATE, the Company's Phase 2 clinical study evaluating efficacy and safety of AV-101, its novel oral NMDA (N-methyl-D-aspartate) receptor glycine site antagonist, as an add-on treatment (together with an FDA-approved oral antidepressant) for adults with major depressive disorder (MDD), several preclinical studies, including studies supporting AV-101's potential for treating neuropathic pain (NP) and levodopa-induced dyskinesia (LID) in patients with Parkinson's disease, and manufacturing activities involving AV-101 and the Company's two novel, clinical-stage neuroactive nasal spray candidates, PH94B for social anxiety disorder (SAD) and PH10 for MDD.

General and administrative expense was approximately \$1.9 million in the fiscal quarter ended June 30, 2019, compared to approximately \$1.5 million in the fiscal quarter ended June 30, 2018. The increase was primarily attributable to noncash stock compensation expense.

At June 30, 2019, VistaGen had cash and cash equivalents of \$8.3 million, compared to \$13.1 million at March 31, 2019.

As of August 13, 2019, there were 42,622,965 shares of common stock outstanding.

About VistaGen

VistaGen Therapeutics is a clinical-stage biopharmaceutical company developing new generation medicines for CNS diseases and disorders where current treatments are inadequate, resulting in high unmet need. VistaGen's <u>pipeline</u> includes three differentiated, clinical-stage CNS drug candidates, AV-101, PH10 and PH94B, each with an exceptional safety profile in all clinical studies to date and therapeutic potential in multiple large and growing CNS markets. For more information, please visit <u>www.vistagen.com</u> and connect with VistaGen on <u>Twitter</u>, <u>LinkedIn</u> and <u>Facebook</u>.

Forward-Looking Statements

This release contains various statements concerning VistaGen's future expectations, plans and prospects, including without limitation, our expectations regarding development and commercialization of our three drug candidates: (i) AV-101 for MDD, NP, LID and suicidal ideation; (ii) PH94B for SAD; and (iii) PH10 for MDD. In addition, statements concerning the Company's future expectations may include statements regarding intellectual property and commercial protection of our drug candidates. Each of these statements constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and may cause actual results to differ materially from those contemplated in these forward-looking statements. Those risks include the following: (i) we may encounter unexpected adverse events in patients during our clinical development of any product candidate that cause us to discontinue further development; (ii) we may not be able to successfully demonstrate the safety and efficacy of our product candidates at each stage of clinical development; (iii) success in preclinical studies or in early-stage clinical trials may not be repeated or observed in ongoing or future studies, and ongoing or future preclinical and clinical results may not support further development of, or be sufficient to gain regulatory approval to market AV-101, PH94B, and/or PH10; (iv) decisions or actions of regulatory agencies may negatively affect the progress of, and our ability to proceed with, further clinical studies or to obtain marketing approval for our drug candidates; (v) we may not be able to obtain or maintain adequate intellectual property protection and other forms of marketing and data exclusivity for our product candidates; (vi) we may not have access to or be able to secure substantial additional capital to support our operations, including our ongoing clinical development activities; and (vii) we may encounter technical and other unexpected hurdles in the manufacturing and development of any of our product candidates. Certain other risks are more fully discussed in the section entitled "Risk Factors" in our most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the Securities and Exchange Commission (SEC). Our SEC filings are available on the SEC's website at www.sec.gov. In addition, any forward-looking statements represent our views only as of the issuance of this release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

VISTAGEN THERAPEUTICS Consolidated Balance Sheets

Amounts in Dollars, except share amounts)

ASSETS Current assets: Cash and cash equivalents \$ 8,297,100 \$ 13,100,300 Receivable from supplier - 300,000 Prepaid expenses and other current assets 482,200 255,000 Total current assets 482,200 312,700 Right of use asset - operating lease 3,833,300 - Security deposits and other assets 47,800 47,800 Total assets 47,800 47,800 47,800 Current liabilities: - 47,800 5 14,011,700 Current liabilities: - 47,800 5 1,055,000 Accound synable \$ 933,900 \$ 1,055,000 - Accound synable \$ 933,900 \$ 1,055,000 - Accound synable \$ 933,900 \$ 1,055,000 - Current notes payable 246,400 57,300 - Operating lease obligation 3,000 3,000 - Total current liabilities: - 341,100 - Accrued express Breferred Stock 4,650,700			June 30, 2019 (Unaudited)		March 31, 2019 (Note 2)	
Cash and cash equivalents \$ 8.297,100 \$ 13,100,300 Receivable from supplier	ASSETS					
Receivable from supplier - 300,000 Prepaid expenses and other current assets 422,600 250,900 Total current assets 625,500 312,700 Right of use asset - operating lease 685,500 312,700 Right of use asset - operating lease 683,3300 67,800 Security deposits and other assets 67,800 \$67,800 Current liabilities: 67,900 \$66,600 Accounts payable \$63,930,900 \$66,600 Current liabilities: 64,000 \$66,600 Accrued expenses 64,000 \$66,000 Current liabilities: 60,000 66,000 Accrued dividends on Series B Preferred Stock 67,000 63,000 Deferred rent liabilities 6,000 63,000 63,000 Non-current liabilities 6,000 63,000 63,000 Non-current liabilities						
Prepaid expenses and other current assets 482,600 250,900 Total current assets 8,779,700 13,851,200 Property and equipment, net 286,500 312,700 Right of use asset - operating lease 3,833,300 - Security deposits and other assets \$ 12,947,300 \$ 14,011,700 Current liabilities: Accourd expenses 1,847,000 1,685,600 Current liabilities: 276,000 1,0686,600 Current liabilities: 3,000,000 3,000 Accourd expenses 1,847,000 1,685,600 Current liabilities: 3,000,000 3,000 Non-current liabilities: 3,000,000 3,000 Non-current liabilities: 3,000,000 3,000 Accrued dividends on Series B Preferred Stock 4,050,700 3,748,200 Deferred rent liabilities: 8,013,100 4,135,600 Total ourrent liabilities 8,013,100 4,135,600 Total ourcurrent liabilities 8,013,100 4,135,600 Total ourcurrent liabilities 8,013,100 4,135,600		\$	8,297,100	\$		
Total current assets 8,779,70 13,651,200 Property and equipment, net 286,500 312,700 Right of use asset - operating lease 3,833,300 - Security deposits and other assets 47,800 47,800 Total assets \$ 12,947,300 \$ 14,011,700 LABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable \$ 933,900 \$ 1,055,000 Accrued expenses 1,847,000 16,885,600 Current notes payable 246,400 57,300 Operating lease oligation 278,100 - Financing lease obligation 3,000 3,000 Total current liabilities: 3,000 3,000 Accrued dividends on Series B Preferred Stock 4,050,700 3,748,200 Deferred rent liabilities 3,956,900 - Financing lease obligation 3,956,900 - Financing lease obligation 5,500 6,300 Total anon-current liabilities 6,936,500 - Total inon-current liabilities 6,936,500			-			
Property and equipment, net 286,500 312,700 Right of use asset - operating lease 3,833,300 - Security deposits and other assets 47,800 47,800 Total assets \$12,947,300 \$14,011,700 Current liabilities: Accounts payable \$93,300 \$1,055,000 Accrued expenses 1,847,000 1,865,600 Current liabilities: 246,400 57,300 Operating lease obligation 3,000 3,000 3,000 Total current liabilities: 3,000 3,000 3,000 3,000 Non-current liabilities: 3,000	Prepaid expenses and other current assets					
Right of use asset - operating lease 3.833.300 - Security deposits and other assets 47,800 47,800 Total assets \$ 12,947.300 \$ 14,011,700 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable \$ 933,900 \$ 1,055,000 Accrued expenses 1,847,000 1,685,600 Current notes payable 246,400 57,300 Operating lease obligation 278,100 - Financing lease obligation 3,000 3,000 3,000 Total current liabilities: 3,000 3,000 2,800,900 Non-current liabilities: 4,050,700 3,748,200 - Operating lease obligation 3,966,900 - 381,100 Operating lease obligation 3,956,900 - 381,100 4,135,600 Operating lease obligation 5,500 6,300 - 381,100 4,135,600 Operating lease obligation 5,500 6,300 - 381,100 4,135,600 Total non-current liabilities						
Security deposits and other assets 47,800 47,800 5 Total assets \$ 12,947,300 \$ 14,011,700 LLABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable \$ 933,900 \$ 1,055,000 Accrued expenses 1,847,000 1,685,600 Current notes payable 246,400 57,300 Operating lease obligation 278,100 - Financing lease obligation 3,000 3,000 Total current liabilities: 3,308,400 2,800,900 Non-current liabilities: 3,308,400 2,800,900 Non-current liabilities: 3,308,400 2,800,900 Accrued dividends on Series B Preferred Stock 4,050,700 3,748,200 Deferred rent liabilities: 3,956,900 - Financing lease obligation 5,500 6,300 Total ourrent liabilities 8,013,100 4,135,600 Total inabilities 8,013,100 4,135,600 Total inabilities 8,013,100 4,135,600 Total inabilities 8,013,100					312,700	
Total assets \$ 12,947,300 \$ 14,011,700 LABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable \$ 933,900 \$ 1,055,000 Accrued expenses 1,847,000 1,865,600 Current notes payable 246,400 57,300 Operating lease oligation 278,100 - Financing lease obligation 3,000 3,000 Total current liabilities: 3,308,400 2,800,900 Non-current liabilities: 3,308,400 2,800,900 Accrued dividends on Series B Preferred Stock 4,050,700 3,748,200 Operating lease obligation 5,500 6,300 Total current liabilities 3,956,900 - Accrued dividends on Series B Preferred Stock 4,050,700 3,748,200 Operating lease obligation 5,500 6,300 Total anon-current liabilities 8,013,100 4,135,600 Total inabilities 11,321,500 6,936,500 Correntiliabilities 11,321,500 6,936,500 11,321,500 <t< td=""><td></td><td></td><td></td><td></td><td>-</td></t<>					-	
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable \$ 933,900 \$ 1,055,000 Accrued expenses 1,847,000 1,885,600 Current notes payable 246,400 57,300 Operating lease obligation 276,100 - Financing lease obligation 3,000 3,000 Total current liabilities: 3,308,400 2,800,900 Non-current liabilities: 4,050,700 3,748,200 Operating lease obligation 3,3956,900 - Financing lease obligation 3,956,900 - Financing lease obligation 5,500 6,300 Operating lease obligation 5,500 6,300 Total non-current liabilities 8,013,100 4,135,600 Total labilities 8,013,100 4,135,600 Total liabilities 8,013,100 4,135,600 Commitments and contingencies 11,321,500 6,936,500 Stockholders' equity: Preferred stock, \$0,000 shares authorized at June 30, 2019 and March 31, 2019 500 Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019 500 500 </td <td></td> <td>_</td> <td>47,800</td> <td></td> <td></td>		_	47,800			
Current liabilities: Accounts payable \$ 933,900 \$ 1,055,000 Accrued expenses 1,847,000 1,685,600 246,400 57,300 Current notes payable 246,400 57,300 278,100 - Financing lease obligation 3,000 3,748,200 5,500 6,300 5,500 6,300 5,500 6,300 5,500 6,300 5,500 6,936,500 11,321,500 6,936,500 11,321,500 6,936,500 11,321,500 6,936,500 500 <td>Total assets</td> <td>\$</td> <td>12,947,300</td> <td>\$</td> <td>14,011,700</td>	Total assets	\$	12,947,300	\$	14,011,700	
Accounts payable \$ 933,900 \$ 1,055,000 Accrued expenses 1,847,000 1,685,600 246,400 57,300 Operating lease oligation 278,100 - - Financing lease obligation 3,000 3,000 3,000 Total current liabilities 3,08,400 2,800,900 - Non-current liabilities: 4,050,700 3,748,200 - Accrued dividends on Series B Preferred Stock 4,050,700 3,748,200 - Deferred rent liabilities: - 381,100 - 381,100 Operating lease obligation 5,500 6,300 - - Total non-current liabilities 8,013,100 4,135,600 - - Total inon-current liabilities 8,013,100 4,135,600 - - - Commitments and contingencies - 500 6,300 - - - Series A Preferred, 500,000 shares authorized at June 30, 2019 and March 31, 2019: 500 500 500 - 500 500	LIABILITIES AND STOCKHOLDERS' EQUITY					
Accrued expenses1,847,0001,685,600Current notes payable246,40057,300Operating lease oligation278,100-Financing lease obligation3,0003,000Total current liabilities3,308,4002,800,900Non-current liabilities:4,050,7003,748,200Deferred rent liabilities4,050,7003,748,200Operating lease obligation3,956,900-Financing lease obligation5,5006,330Total non-current liabilities8,013,1004,135,600Total non-current liabilities8,013,1004,135,600Total non-current liabilities8,013,1004,135,600Commitments and contingencies11,321,5006,936,500Stockholders' equity:Preferred stock, \$0,001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:500Series A Preferred, 500,000 shares authorized at June 30, 2019 and March 31, 2019:500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019:500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019:1,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,200	Current liabilities:					
Current notes payable246,40057,300Operating lease oligation278,100278,100Financing lease obligation3,0003,000Total current liabilities3,308,4002,800,900Non-current liabilities:4,050,7003,748,200Deferred rent liability381,1003,956,900Operating lease obligation3,956,900-Financing lease obligation5,5006,300Total non-current liabilities8,013,1004,135,600Total non-current liabilities8,013,1004,135,600Commitments and contingencies11,321,5006,936,500Stockholders' equity:Preferred stock, \$0,001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:500Series A Preferred, 500,000 shares authorized at June 30, 2019 and March 31, 2019500500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 20191,2001,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,2001,200	Accounts payable	\$	933,900	\$	1,055,000	
Operating lease oligation278,100Financing lease obligation3,000Total current liabilities3,000Accrued dividends on Series B Preferred Stock4,050,700Deferred rent liabilities:4,050,700Accrued dividends on Series B Preferred Stock4,050,700Deferred rent liabilities:3,956,900Accrued dividends on Series B Dreferred Stock4,050,700Operating lease obligation3,956,900Financing lease obligation5,500Total non-current liabilities8,013,100At 135,60011,321,500Total liabilities6,936,500Commitments and contingencies11,321,500Stockholders' equity:Preferred stock, \$0,001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:Series A Preferred, 500,000 shares authorized at June 30, 2019 and March 31, 2019:Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 sharesissued and outstanding at June 30, 2019 and March 31, 2019; 2,318,012 shares	Accrued expenses		1,847,000		1,685,600	
Financing lease obligation3,000Total current liabilities:3,308,400Accrued dividends on Series B Preferred Stock4,050,700Deferred rent liabilities:4,050,700Accrued dividends on Series B Preferred Stock4,050,700Operating lease obligation3,956,900Operating lease obligation5,500Financing lease obligation5,500Total non-current liabilities8,013,100At 1,356,60011,321,500Total non-current liabilities8,013,100Commitments and contingencies11,321,500Stockholders' equity:500Preferred, 500,000 shares authorized at June 30, 2019 and March 31, 2019:500Series A Preferred, 500,000 shares authorized at June 30, 2019 and March 31, 2019500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 20191,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares1,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,200	Current notes payable		246,400		57,300	
Total current liabilities3,308,4002,800,900Non-current liabilities: Accrued dividends on Series B Preferred Stock4,050,7003,748,200Deferred rent liability-381,100Operating lease obligation3,956,900-Financing lease obligation5,5006,300Total non-current liabilities8,013,1004,135,600Total inbilities11,321,5006,936,500Commitments and contingencies11,321,5006,936,500Stockholders' equity: Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019: Series A Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019500Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 20191,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,200	Operating lease oligation		278,100		-	
Non-current liabilities:Accrued dividends on Series B Preferred Stock4,050,7003,748,200Deferred rent liability-381,100Operating lease obligation3,956,900-Financing lease obligation5,5006,300Total non-current liabilities8,013,1004,135,600Total liabilities11,321,5006,936,500Commitments and contingencies5tockholders' equity:Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:500Series A Preferred, 500,000 shares authorized, issued and outstanding at June 30, 2019 and March 31, 2019:500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019:1,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019:1,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019:1,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019:1,200	Financing lease obligation		3,000		3,000	
Accrued dividends on Series B Preferred Stock4,050,7003,748,200Deferred rent liability-381,100Operating lease obligation3,956,900-Financing lease obligation5,5006,300Total non-current liabilities8,013,1004,135,600Total liabilities11,321,5006,936,500Total liabilities0,010 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:500Series A Preferred, 500,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares500Series B Preferred; 4,000,000 shares authorized at June 30, 2019; 1,160,240 shares500issued and outstanding at June 30, 2019 and March 31, 2019; 1,2001,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019; 1,160,240 shares1,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,2001,200	Total current liabilities	=	3,308,400	_	2,800,900	
Deferred rent liability-381,100Operating lease obligation3,956,900-Financing lease obligation5,5006,300Total non-current liabilities8,013,1004,135,600Total liabilities11,321,5006,936,500Commitments and contingenciesStockholders' equity:Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:500Series A Preferred, 500,000 shares authorized, issued and outstanding at June 30, 2019 and March 31, 2019; 1,160,240 shares500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares1,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,200	Non-current liabilities:					
Operating lease obligation3,956,900-Financing lease obligation5,5006,300Total non-current liabilities8,013,1004,135,600Total liabilities11,321,5006,936,500Commitments and contingenciesStockholders' equity:Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:500Series A Preferred, 500,000 shares authorized at June 30, 2019 and March 31, 2019:500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares1,200issued and outstanding at June 30, 2019 and March 31, 2019; 2,318,012 shares1,200	Accrued dividends on Series B Preferred Stock		4,050,700		3,748,200	
Financing lease obligation5,5006,300Total non-current liabilities8,013,1004,135,600Total liabilities11,321,5006,936,500Commitments and contingencies11,321,5006,936,500Stockholders' equity:Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:500Series A Preferred, 500,000 shares authorized, issued and outstanding at June 30, 2019 and March 31, 2019500500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares1,2001,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,2001,200	Deferred rent liability		-		381,100	
Total non-current liabilities8,013,1004,135,600Total liabilities11,321,5006,936,500Commitments and contingencies6,936,500Stockholders' equity:Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:Series A Preferred, 500,000 shares authorized, issued and outstanding at June 30, 2019 and March 31, 2019500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares1,200issued and outstanding at June 30, 2019 and March 31, 2019; 2,318,012 shares1,200	Operating lease obligation		3,956,900		-	
Total liabilities11,321,5006,936,500Commitments and contingenciesCommitments and contingenciesCommitments and contingenciesCommitments and contingenciesStockholders' equity: Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019: Series A Preferred, 500,000 shares authorized, issued and outstanding at June 30, 2019 and March 31, 2019500500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares issued and outstanding at June 30, 2019 and March 31, 2019; 1,2001,2001,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,2001,200	Financing lease obligation		5,500		6,300	
Commitments and contingencies Stockholders' equity: Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019: Series A Preferred, 500,000 shares authorized, issued and outstanding at June 30, 2019 and March 31, 2019 500 500 Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares issued and outstanding at June 30, 2019 and March 31, 2019; 1,160,240 shares issued and outstanding at June 30, 2019 and March 31, 2019; 1,200 1,200 Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares	Total non-current liabilities		8,013,100		4,135,600	
Stockholders' equity:Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:Series A Preferred, 500,000 shares authorized, issued and outstanding at June 30, 2019 and March 31, 2019500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares500issued and outstanding at June 30, 2019 and March 31, 20191,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,200	Total liabilities	=	11,321,500	_	6,936,500	
Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:500500Series A Preferred, 500,000 shares authorized, issued and outstanding at June 30, 2019 and March 31, 2019500500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares1,2001,200issued and outstanding at June 30, 2019 and March 31, 20191,2001,2001,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,2001,200	Commitments and contingencies					
Series A Preferred, 500,000 shares authorized, issued and outstanding at June 30, 2019 and March 31, 2019500500Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares1,2001,200issued and outstanding at June 30, 2019 and March 31, 20191,2001,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,200	Stockholders' equity:					
Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 sharesissued and outstanding at June 30, 2019 and March 31, 20191,200Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares1,200	Preferred stock, \$0.001 par value; 10,000,000 shares authorized at June 30, 2019 and March 31, 2019:					
issued and outstanding at June 30, 2019 and March 31, 2019 1,200 1,200 Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares	Series A Preferred, 500,000 shares authorized, issued and outstanding at June 30, 2019 and March 31, 2019		500		500	
Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares	Series B Preferred; 4,000,000 shares authorized at June 30, 2019 and March 31, 2019; 1,160,240 shares					
	issued and outstanding at June 30, 2019 and March 31, 2019		1,200		1,200	
issued and outstanding at June 30, 2019 and March 31, 2019 2, 300 2, 300 2, 300	Series C Preferred; 3,000,000 shares authorized at June 30, 2019 and March 31, 2019; 2,318,012 shares					
	issued and outstanding at June 30, 2019 and March 31, 2019		2,300		2,300	
Common stock, \$0.001 par value; 100,000,000 shares authorized at June 30, 2019 and March 31, 2019;	Common stock, \$0.001 par value; 100,000,000 shares authorized at June 30, 2019 and March 31, 2019;					
42,758,630 shares issued and outstanding at June 30, 2019 and March 31, 2019 42,800 42,800	42,758,630 shares issued and outstanding at June 30, 2019 and March 31, 2019		42,800			
Additional paid-in capital 192,890,400 192,129,900	Additional paid-in capital		192,890,400		192,129,900	
Treasury stock, at cost, 135,665 shares of common stock held at June 30, 2019 and March 31, 2019 (3,968,100) (3,968,100)	Treasury stock, at cost, 135,665 shares of common stock held at June 30, 2019 and March 31, 2019		(3,968,100)		(3,968,100)	

Accumulated deficit

Total stockholders' equity

Total liabilities and stockholders' equity

(187,343,300)	((181,133,400)		
	1,625,800		7,075,200		
\$	12,947,300	\$	14,011,700		

VISTAGEN THERAPEUTICS STATEMENT OF OPERATIONS

Amounts in Dollars, except share amounts (Unaudited)

		Three Months Ended June 30,		
	2019	2018		
Operating expenses:				
Research and development	\$ 4,313,900	\$ 2,743,700		
General and administrative	1,910,100	1,466,300		
Total operating expenses	6,224,000	4,210,000		
Loss from operations	(6,224,000)	(4,210,000)		
Other income (expenses), net:				
Interest income (expense), net	16,500	(2,100)		
Loss before income taxes	(6,207,500)	(4,212,100)		
Income taxes	(2,400)	(2,400)		
Net loss and comprehensive loss	\$ (6,209,900)	\$ (4,214,500)		
Accrued dividend on Series B Preferred stock	(302,500)	(273,500)		
Net loss attributable to common stockholders	\$ (6,512,400)	\$ (4,488,000)		
Basic and diluted net loss attributable to common				
stockholders per common share	\$ (0.15)	\$ (0.20)		
Weighted average shares used in computing				
basic and diluted net loss attributable to common				
stockholders per common share	42,622,965	22,987,066		
Company Contact				
Mark A. McPartland VistaGen Therapeutics Inc.				

VistaGen Therapeutics Inc. Phone: +1 (650) 577-3600 Email: IR@vistagen.com

Investor Contact

Valter Pinto / Allison Soss KCSA Strategic Communications Phone: +1 (212) 896-1254/+1 (212) 896-1267 Email: <u>VistaGen@KCSA.com</u>

Media Contact

Caitlin Kasunich / Lisa Lipson KCSA Strategic Communications Phone: +1 (212) 896-1241/+1 (508) 843-6428 Email: <u>VistaGen@KCSA.com</u>

SOURCE: VistaGen Therapeutics

Released August 13, 2019